Drug intelligence / Profile preview

LDN-071

Development stage: Preclinical
Lead developer: Ladon Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

LDN-071 is a novel, first-in-class, targeted oral therapy developed by Ladon Therapeutics for the treatment of inflammatory bowel disease (IBD). It is designed using the A3SMO platform to act locally in the gastrointestinal tract and is resistant to enzymatic digestion. The drug aims to provide local immunosuppression, overcoming resistance to biological therapies and reducing intestinal inflammation. LDN-071 represents a new molecular entity with a unique mechanism focused on localized action within the gut.

Targets

PAI-1 (Plasminogen activator inhibitor type 1)

Beyond the preview

Go deeper on LDN-071.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LDN-071.

Explore the full profile